(HealthDay News) – A model shows that replacing the current 23-valent pneumococcal polysaccharide vaccine (PPSV23) with the 13-valent pneumococcal conjugate vaccine (PCV13) might prevent more ...

A cohort study found that influenza and 23-valent pneumococcal polysaccharide vaccines (PPSV23) can reduce the risk of chronic obstructive pulmonary disease (COPD)- and pneumonia-related ...

The PPSV23 vaccine has been shown to have efficacy rates of 60% to 70% in helping to prevent invasive disease caused by serotypes covered by the vaccine. PCV15 and PCV20 are still too new to have good ...

The Advisory Committee on Immunization Practices (ACIP) has revised its interval recommendations for the pneumococcal polysaccharide vaccine (PPSV23) and pneumococcal conjugate vaccine (PCV13) in ...

study confirms shingles vaccine effective in elderly with ESRD ACIP changed the recommended interval between PCV13 followed by PPSV23 (PCV13-PPSV23 sequence) from 6-12 months to ≥1 year for ...

Eligibility for a government-funded pneumococcal polysaccharide vaccine (PPSV23) would be expanded to people aged 50 to 64, effective immediately, but only until the remaining vaccines are used up, ...

Pneumococcal vaccines, like PCV13 and PPSV23, protect against serious infections caused by Streptococcus pneumoniae bacteria, which can affect children, older adults, and those with chronic health ...

—New data suggest that co-administration of the shingles and pneumonia vaccines in adults ages 50 and over is safe and just as immunogenic as when given sequentially. Reviewed by Ware Kuschner, MD, ...